EYLEA® extended dosing can reduce the treatment burden for you and your patients1,2
57% of patients had a next intended injection interval of ≥12 weeks in the ALTAIR study at the end of Year 13,a
- Up to 41% of patients had a next intended injection interval of 16 weeks3,a
a The ‘next intended injection interval’ was defined as the time between the last injection and the next scheduled injection at the final study visit at Week 52.
- Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-2548.
- EYLEA® (aflibercept solution for injection) Summary of Product Characteristics. Berlin, Germany: Bayer Pharma AG; July 2018.
- Okada AA, Takahashi K, et al. Use of Intravitreal Aflibercept Treat-and-Extend Dosing for Wet Age-Related Macular Degeneration: 52-Week ALTAIR Results. Poster presented at the American Academy of Ophthalmology (AAO) Congress New Orleans, LA, November 11–14, 2017. Available from: https://aao.scientificposters.com/epsWelcome.cfm?CFID=6335346&CFTOKEN=47c8b80ef1e0478c-3912E1EF-E986-D0BE-7EE9563148B676EF.